Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erica is a brand name for the pharmaceutical drug Pregabalin. Pregabalin is an anticonvulsant, analgesic, and anxiolytic medication. Its primary mechanism of action involves binding to the alpha2delta subunit of voltage-dependent calcium channels. This binding modulates the release of several excitatory neurotransmitters, including glutamate, substance-P, norepinephrine, and calcitonin gene-related peptide. It is used to treat various conditions such as neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, pain associated with spinal cord injury, and as an adjunctive therapy for partial-onset seizures in adults, as well as generalized anxiety disorder. [3, 7, 8, 10, 19, 20, 21]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Erica.